Complete and send this form, significant in applicable feet(s), to: Mail SP 3 9 200 DISTRUCTION: The form should so, before the the New Location of Tex Ex. DISTRUCTION: The form should so, before the the New Location of Tex Ex. DISTRUCTION: The form should so, before the the New Location of Tex Ex. DISTRUCTION: The form should so, before the New Location of Tex Ex. DISTRUCTION: The form should so, before the New Location of Tex Ex. DISTRUCTION: The form should so, before the New Location of Tex Ex. DISTRUCTION: The form should so, before the New Location of Tex Ex. DISTRUCTION: The form should so, before the New Location of Tex Ex. DISTRUCTION: The form should so completed when the support of the New Location in the New Locati	_ ,	TELEN	PART B	- FEE(S)	TRANSMITTAL		\$
NSTRUCTIONS: The form should be died for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Block at through 5 should be completed when appropriate, all further groups and softeness and nonfideration of maintenance fees and installation. The property of the p	/	295√	h applicable fe		Commissioner fo P.O. Box 1450 Alexandria, Virg	or Patents	A
CURRENT COMERCENDROST CADRESS (Note: Use thea's for my sharge of address) 2898 7390 08242004 NEW ENGLAND BIOLABS, INC. 32 TOZER ROAD BEVERLY, MA 01915 10/01/2004 FFABAIRS 0000044 09786009. 10 FC12501 APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOOKET NO. CONTRIBUTION NO. 97786,009 04417.2001 APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOOKET NO. CONTRIBUTION NO. 97786,009 04417.2001 TITLE OF INVENTION: INTELIN MEDIATED PEPTIDE LIGATION APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOOKET NO. CONTRIBUTION NO. 97786,009 04417.2001 APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOOKET NO. CONTRIBUTION NO. 97786,009 04417.2001 APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOOKET NO. CONTRIBUTION NO. 97786,009 04417.2001 APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOOKET NO. CONTRIBUTION NO. 97786,009 04417.2001 APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOOKET NO. CONTRIBUTION NO. 97786,009 04417.2001 APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOOKET NO. CONTRIBUTION NO. 97786,009 04417.2001 APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOOKET NO. CONTRIBUTION NO. 97786,009 04417.2001 APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOOKET NO. CONTRIBUTION NO. 97786,009 04417.2001 APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOOKET NO. CONTRIBUTION NO. 97786,009 04417.2001 APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOOKET NO. CONTRIBUTION NO. 97786,009 04417.2001 APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOOKET NO. CONTRIBUTION NO. 97786,009 04417.2001 APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOOKET NO. CONTRIBUTION NO. 97786,009 04417.2001 APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOOKET NO. CONTRIBUTION NO. 97786,009 04417.2001 APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOOKET NO. CONTRIBUTION NO. 97786,009 04417.2001 APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY	DISTRUCTIONS, This Co	and the state of the same	mitting the ICCLU	_		ind) Dining to 1.5	1
September 28 Sept	appropriate. All further co indicated unless corrected maintenance fee notificatio	rm should be used for train rrespondence including the F	Patent, advance ordin Block 1, by (a)	lers and notif specifying a	ication of maintenance fees values correspondence address	will be mailed to the current; and/or (b) indicating a separate	nould be completed where correspondence address as arate "FEE ADDRESS" for
NEW ENGLAND BIOLABS, INC. 32 TOZER ROAD BEVERLY, MA 1915 10/01/2004 FFRNNIR3 00000044 09786009. 10 FC:2501 APPLICATION NO. FILING DATE PC:2501 APPLICATION NO. FILING DATE PLESS DATE OF INVENTION: INTERN MEDIATED PEPTIDE LIGATION Ming-Qun XU NEB-150PUS 6390 TITLE OF INVENTION: INTERN MEDIATED PEPTIDE LIGATION APPLIN TYPE MALLENTITY SSUE-FRE PUBLICATION FEE TOTAL FEE(5) DUE APPLIN TYPE MALLENTITY SSUE-FRE PUBLICATION FEE TOTAL FEE(5) DUE APPLIN TYPE MALLENTITY SSUE-FRE PUBLICATION FEE TOTAL FEE(5) DUE APPLIN TYPE MACHINER ART UNIT CLASS-SUECLASS 1. (A bange of correspondence address or indication of "Fee Address" (17 CR 1 1:63) Change of correspondence address (or Change of Co			any change of address)		Note: A certificate of Fee(s) Transmittal. The papers. Each addition	mailing can only be used fais certificate cannot be used al paper, such as an assignment	or domestic mailings of the for any other accompanying ent or formal drawing, mus
32 TOZER ROAD BEVERLY, MA 01915 10/01/2004 FFBMRIB3 0000044 09786009 10 FC:2501 30.00 ID APPLICATION NO. FILING DATE FIRST NAMED INVENTOR APPLICATION NO. FILING DATE APPLICATION NO. FILING DATE FIRST NAMED INVENTOR APPLICATION NO. FILING DATE APPLICATION NO. FILING DATE FIRST NAMED INVENTOR APPLICATION NO. FILING DATE APPLICATION NO. FILING DATE FIRST NAMED INVENTOR APPLICATION NO. FILING DATE FIRST NAMED INVENTOR APPLICATION NO. FILING DATE APPLICATION NO. FILING DATE FIRST NAMED INVENTOR APPLICATION NO. FILING DATE FIRST NAMED INVENTOR FIRST NAMED INVENTOR APPLICATION NO. FILING DATE FIRST NAMED INVENTOR APPLICATION NO. FILING DATE FIRST NAMED INVENTOR FIRST NAMED INVENTO					have its own certificat	e of mailing or transmission.	
Lest/e GoldMerg	· · · · · · · · · · · · · · · · · · ·				Ce I hereby certify that the	rtificate of Mailing or Tran his Fee(s) Transmittal is bein	smission g deposited with the United
Lest/e GoldMerg	BEVERLY, MA 01915		•		States Postal Service addressed to the Mai	with sufficient postage for fit I Stop ISSUE FEE address	st class mail in an envelope above, or being facsimile
Change of correspondence address or indication of "Fee Address" (17 CFR 1.563). Change of correspondence address or indication of "Fee Address" (18 changes of correspondence address or indication of "Fee Address" (18 changes of correspondence address or indication of "Fee Address" (18 changes of correspondence address or indication of "Fee Address" (18 changes of correspondence address or indication of "Fee Address" (18 changes of correspondence address or indication of "Fee Address" (18 changes of correspondence address or indication of "Fee Address" (18 changes of correspondence address or indication of "Fee Address" (18 changes of correspondence address or indication of "Fee Address" (18 changes of correspondence address or indication of "Fee Address" (18 changes of correspondence address or indication of "Fee Address" (18 changes of correspondence address or indication of "Fee Address" (18 changes of correspondence address or indication of "Fee Address" (18 changes of correspondence address or indication of "Fee Address" (18 changes of correspondence address or indication of "Fee Address" (18 changes of correspondence address or indication of "Fee Address" (18 changes of correspondence address or indication of "Fee Address" (18 changes OR alternatively, (2) the name of a greater patent attorney as a member a present of the patent of the patent attorney or a segment of the changes OR alternatively, (2) the name of a greater patent attorney or a segment of the patent or type) (2) the name of a greater patent attorney or a segment of the patent or type) (2) the name of a greater patent attorney or a segment of the patent or type) (2) the name of a greater patent attorney or a segment of the changes OR alternatively, (2) the name of a greater patent attorney or a segment of the or and single firm (having as a member a greater) or the patent or type) (2) the name of a greater patent attorney or great. If no name is 18 changes OR alternatively, (2) the name of a greater patent attorney or great. If no name is	, 10/01/2004 FFANAIA3 0000	0044 09786009					
APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 097/86,009 0417/2001 Ming-Qun Xu NEB-150PUS 6390 TITLE OF INVENTION: INTEIN MEDIATED PEPTIDE LIGATION APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 097/86,009 0417/2001 Ming-Qun Xu NEB-150PUS 6390 TITLE OF INVENTION: INTEIN MEDIATED PEPTIDE LIGATION APPLICATION NO. FILING DATE DUE DATE DUE DATE DUE nonprovisional YES \$665 \$0 \$665 11/24/2004 EXAMINER ART UNIT CLASS-SUBCLASS MOORE, WILLIAM W 1652 435-011000 1. Change of correspondence address (or Change of Correspondence Address from PTO/SB1/22) attached. 1. Change of correspondence address (or Change of Correspondence Address from PTO/SB1/22) attached. 1. Change of correspondence address (or Change of Correspondence Address from PTO/SB1/22) attached. 1. Change of correspondence address (or Change of Correspondence Address from PTO/SB1/22) attached. 1. Change of correspondence address (or Change of Correspondence Address from PTO/SB1/22) attached. 2. For printing on the patent from page, list or agreement of the names of up to 2 registered patent antomeys or agents. If no name is 3 listed, no name will be printed. 2. For printing on the patent from page, list or agents OR, alternatively. 2. For printing on the patent from page, list or agents or agent or agent or agent or agent or agent o					"- 61 61 d	had I been	
APPLICATION NO. FILING DATE	02 FC:8001	. 30.00 UP			September 2	8 2004	(Date)
O9/786,009 04/17/2001 Ming-Qun Xu NEB-150PUS 6390 TITLE OF INVENTION: INTERN MEDIATED PEPTIDE LIGATION APPLN TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE nonprovisional YES \$665 \$0 \$665 11/24/2004 EXAMINER ART UNIT CLASS-SUBCLASS MOORE, WILLIAM W 1652 435-011000 1. Change of correspondence address of indication of "Fee Address" (37 CFR 1.363). CIANGE of Correspondence address of indication of "Fee Address" (37 CPR 1.363). Or an expectation of "Fee Address" indication of "Fee Address" (37 CPR 1.363). Or an expectation of "Fee Address" indication of "Fee Address" (37 CPR 1.363). Or an expectation of "Fee Address" indication of "Fee Address" (37 CPR 1.363). Or an expectation of "Fee Address" indication form PTIO/SB/122) attached. Or an expectation of "Fee Address" indication form PTIO/SB/122) attached. Or an expectation of "Fee Address" indication form PTIO/SB/122) attached. Or an expectation of "Fee Address" indication form PTIO/SB/122) attached. Or an expectation of "Fee Address" indication form PTIO/SB/122) attached. Or an expectation of "Fee Address" indication form PTIO/SB/122) attached. Or an expectation of "Fee Address" indication form PTIO/SB/122) attached. Or an expectation of "Fee Address" indication form PTIO/SB/122) attached. Or an expectation of "Fee Address" indication form PTIO/SB/122) attached. Or an expectation of "Fee Address" indication form PTIO/SB/122) attached. Or an expectation of "Fee Address" indication form PTIO/SB/122) attached to the patent attorneys or agents. If no name is a state of the printed of the printed. Or an expectation of the fee(s) is enclosed. Or an expectation of t	APPLICATION NO	FILING DATE	τ	IDET NAMED	-		
APPLN. TYPE SMALL ENTITY ISSUE-FRE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE nonprovisional YES \$665 \$0 \$665 11/24/2004 EXAMINER ART UNIT CLASS-SUBCLASS MOORE, WILLIAM W 1652 435-011000 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1,563). Change of correspondence address (or Change of Correspondence Address form PTO/SB47, Rev 03-02 or more recent) attached. Use of a Customer Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) New England Biolabs, Inc. Beverly, MA Please check the appropriate assignee category or categories (will not be printed on the patent): \(\frac{1}{2} \) Individual \(\frac{1}{2} \) Corporation or other private group entity \(\frac{1}{2} \) Government 4a. The following fee(s) are enclosed: Publication Fee (No small entity discount permitted) A. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. \(\frac{1}{2} \) A check in the amount of the fee(s) is enclosed. Payment of Fee(s): A check in the amount of the fee(s) is enclosed. \(\frac{1}{2} \) Payment of Fee(s): A check in the amount of the fee(s) is enclosed. \(\frac{1}{2} \) Payment of Fee(s): A check in the amount of the fee(s) is enclosed. \(\frac{1}{2} \) Payment of Fee(s): A check in the amount of the fee(s) is enclosed. \(\frac{1}{2} \) Payment of Fee(s): A check in the amount of the fee(s) is enclosed. \(\frac{1}{2} \) Payment of Fee(s): A check in the amount of the fee(s) is enclosed. \(\frac{1}{2} \) Payment of Fee(s): A check in the amount of the fee(s) is enclosed. \(\frac{1}{2} \) Payment of Fee(s): A check in the amount of the fee(s) is enclosed. \(\frac{1}{2} \)		1					
APPLN TYPE SMALL ENTITY ISSUE-FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE nonprovisional YES \$665 \$0 \$665 11/24/2004 EXAMINER ART UNIT CLASS-SUBCLASS MOORE, WILLIAM W 1652 435-011000 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). Change of correspondence address (or Change of Correspondence Address form PTO/SB147; Rev 03-02 or more recent) attached. "Fee Address" indication (or "Fee Address" address" address indicated and the properties of the patent attorneys or agents OR, alternatively, (2), the names of up to 3 registered patent attorneys or agents. If no name is 18 miles, no name will be printed. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) New England Biolabs, Inc. Beverly, MA Please check the appropriate assignee category or categories (will not be printed on the patent): Implication for (No small entity discount permitted) Advance Order - # of Copies 10 Payment by credit card. Form PTO-2038 is attached. Payment by credit card. Form PTO-2038 is attached. Payment by credit card. Form PTO-2038 is attached. Payment by credit card. Form PTO-2038 is attached. The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to people in the patent of the count Number (encloses an extra copy of this form). 5. Change in Entity Status (from status indicated above) A Applicant claims SNALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Public	·			Ming-Q	uii Au	NED-130FUS	0390
nonprovisional YES \$665 \$0 \$65 \$11/24/2004 EXAMINER ART UNIT CLASS-SUBCLASS MOORE, WILLIAM W 1652 435-011000 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.563). Change of correspondence address (or Change of Correspondence Address form PTO/SB/12; hatched. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. Change of correspondence address or indication form PTO/SB/122 (attached. Change of correspondence address or indication form PTO/SB/122 (attached. Change of correspondence address or indication form PTO/SB/122 (attached. Change of correspondence address or indication form PTO/SB/122 (attached. Change of correspondence address or indication for PTEP ATENT (print or type) attached. Change in Change of correspondence address (or Change of Correspondence Address form part of PTO/SB/122) attached. Change in Change in Change of Correspondence address for Change in Ch							
Class Subclass	APPLN. TYPE	SMALL ENTITY	issye.fe	EE\	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
MOORE, WILLIAM W 1652 435-011000 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). CFR 1.363). CFR 1.363). Change of correspondence address (or Change of Correspondence Address for PTO/SB/12) attached. The Address of midication of "Fee Address" Indication form PTO/SB/12) attached. The Address of midication of "Fee Address" Indication form PTO/SB/12 patched. The Address of midication of "Fee Address" Indication form PTO/SB/12 patched. The Address indication of "Fee Address" Indication form PTO/SB/12 patched. The Address indication of "Fee Address" Indication form PTO/SB/12 patched. The Address indication of "Fee Address" Indication form PTO/SB/12 patched. The Address indication of the Fee Address indication form PTO/SB/12 patched. The Director of the USPTO is required it apply the Issue Fee and Publication Fee (if required) will not be a price or other party in interest as shown by the records of the United States Patent and Trademark Office. Authorized Signature Moore of Assignature Date September 28, 2004	nonprovisional	nonprovisional YES		1	\$0	\$665	11/24/2004
1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). CFR 1.363). CFR 1.363). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. CFR 1.363). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. CR 1.363). CR 1.363). CR 1.363). CR 2. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. CR 2. Change in Entity Status (from status indicated above) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) New England Biolabs, Inc. Beverly, MA Please check the appropriate assignee category or categories (will not be printed on the patent): Beverly, MA Please check the appropriate assignee category or categories (will not be printed on the patent): Beverly, MA Please check the appropriate assignee category or categories (will not be printed on the patent): A check in the amount of the fee(s) is enclosed. Payment by credit card. Form PTO-2038 is attached. A check in the amount of the fee(s) is enclosed. Payment by credit card. Form PTO-2038 is attached. Change in Entity Status (from status indicated above) A check in the amount of the fee(s) is enclosed. Payment by credit card. Form PTO-2038 is attached. Change in Entity Status (from status indicated above) A check in the amount of the fee(s) is enclosed. Change in Entity Status (from status indicated above) A check in the amount of the fee(s) is enclosed. Change in Entity Status (from status indicated above) A check in the amount of the fee(s) is enclosed. Change in Entity Status (from status indicated above) Change in Entity Status (from status indicated above) A check in the amount of the	EXAM	EXAMINER		T .	CLASS-SUBCLASS]	
CFR 1.363). CFR 1.363). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. Change of correspondence address for Change of Correspondence Address form PTO/SB/122) attached. Change of correspondence address for Change of Correspondence Address form PTO/SB/122) attached. Change of correspondence address for Change of Correspondence Address form PTO/SB/122) attached. Change of Correspondence address for Change of Correspondence address form PTO/SB/122 attached. Change of Correspondence address for Change of Correspondence address form PTO/SB/122 attached. Change of Correspondence address for Change of Correspondence address form PTO/SB/122 attached. Change of Correspondence address for Change of Correspondence address form PTO/SB/122 attached. Change in Entity Status (from status indicated above) Laptoplication Fee (No small entity discount permitted) Schange in Entity Status (from status indicated above) Laptoplication Fee (No Small Entity Status (from status indicated above) Schange in Entity Status (from status indicated above) Authorized Signature CFR 1.363). (1) the names of up to 3 registered patent attorneys or agents. If no name is a significant claims of up to 2 significant claims and member a registered attorney or agents. If no name is listed, no name is listed, no name will be printed. Change in Entity Status (from Status indicated above) Change in Entity Status (from status indicated above) Authorized Signature CFR 1.27 (Exp 2.204) Change in Entity Status (from status indicated above) Date September 28, 2004	MOORE, V	MOORE, WILLIAM W		1652			
PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) New England Biolabs, Inc. Beverly, MA Please check the appropriate assignee category or categories (will not be printed on the patent): Individual Corporation or other private group entity Government of the fee(s) are enclosed: 4b. Payment of Fee(s): A check in the amount of the fee(s) is enclosed. Payment by credit card. Form PTO-2038 is attached. Payment by credit card. Form PTO-2038 is attached. Payment by credit card. Form PTO-2038 is attached. The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number (enclose an extra copy of this form). 5. Change in Entity Status (from status indicated above) a Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent, or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.	CFR 1.363). Change of correspondence address (or Change of Correspond Address form PTO/SB/122) attached. "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Cust			(1) the names of up to 3 registered patent attorneys or agents OR, alternatively, (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is			
PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) New England Biolabs, Inc. Beverly, MA Please check the appropriate assignee category or categories (will not be printed on the patent): A. The following fee(s) are enclosed: A. The following fee(s) are enclosed: Publication Fee (No small entity discount permitted) Advance Order - # of Copies 10 The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number (enclose an extra copy of this form). 5. Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.	3. ASSIGNEE NAME AND	RESIDENCE DATA TO B	E PRINTED ON T	HE PATENT	(print or type)	<u></u>	
Please check the appropriate assignee category or categories (will not be printed on the patent): 4a. The following fee(s) are enclosed: 4b. Payment of Fee(s): 4b. Payment of Fee(s): 4b. Payment of Fee(s): 4c. The following fee(s) are enclosed: 4d. Publication Fee (No small entity discount permitted) 4d. Advance Order - # of Copies 10 4d. Publication Fee (No small entity discount permitted) 4d. Advance Order - # of Copies 10 4d. Payment by credit card. Form PTO-2038 is attached. 4d. Payment by credit card. Form PTO-20	PLEASE NOTE: Unless recordation as set forth in	s an assignee is identified be n 37 CFR 3.11. Completion of	low, no assignee of of this form is NOT	lata will appe a substitute f	ar on the patent. If an assign or filing an assignment.	nee is identified below, the d	ocument has been filed for
Please check the appropriate assignee category or categories (will not be printed on the patent): 4a. The following fee(s) are enclosed: 4b. Payment of Fee(s): 4c. Care in the amount of the fee(s) is enclosed. 4c. Publication Fee (No small entity discount permitted) 4c. Payment of Fee(s): 4b. Payment of Fee(s): 4c. Care in Entity Status (from Status indicated above) 4c. Payment of Fee(s): 4c. Care in Entity Status (from Status indicated above) 4c. Payment of Fee(s): 4c. Care in Entity Status (from Status indicated above) 4c. Payment of Fee(s): 4c. Care in Entity Status (from Status indicated above) 4c. Payment of Fee(s): 4c. Payment of Fee(s): 4c. Care in Entity Status (from Status indicated above) 4c. Care in Entity Status (from Status indicated above) 4c. Payment of Fee(s): 4c. Care in Entity Status (from Status indicated above) 4c. Care in Entity Status (from Status indicated above) 4c. Care in Entity Status (from Status indicated above) 4c. Care in Entity Status (from Status indicated above) 4c. Care in Entity Status (from Status indicated above) 4c. Care in Entity Status (from Status indicated above) 4c. Care in Entity Status (from Status indicated above) 4c. Care in Entity Status (from Status indicated above) 4c. Care in Entity Status (from Status indicated above) 4c. Care in Entity Status (from Status indicated above) 4c. Care in Entity Status (from Status indicated above) 4c. Care in Entity Status (from Status indicated above) 4c. Care in Entity Status (from Status indicated above) 4c. Care in Entity Status (from Status indicated above) 4c. Care in Entity Status (from Status indicated above) 4c. Care in Entity Status (from Status indicated above) 4c. Care in Entity Status (from Status indicated above) 4c. Care in Entity Status (from Status indicated above) 4c. Care in Entity Status (from Status indicated above) 4c. Care in Entity Status (from Statu							
4a. The following fee(s) are enclosed: Solution So	New Englan	d Biolabs, Inc.		Bev	verly, MA		
4a. The following fee(s) are enclosed: Solution So	m total				. V)		. 🗅
A check in the amount of the fee(s) is enclosed. Publication Fee (No small entity discount permitted) Advance Order - # of Copies 10 Deposit Account Number the Deposit Account Number (enclose an extra copy of this form). Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. Deposit Account Number to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office. Date September 28, 2004						orporation or other private gr	oup entity Government
Publication Fee (No small entity discount permitted) Advance Order - # of Copies 10 The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number (enclose an extra copy of this form). 5. Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office. Date September 28, 2004		cherosed.				closed.	
Deposit Account Number					. ,		
5. Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office. Date September 28, 2004	Advance Order - # o	f Copies 10		The Direct	ctor is hereby authorized by c	harge the required fee(s), or	credit any overpayment, to
The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party ir interest as shown by the records of the United States Patent and Trademark Office. Date September 28, 2004)				
Authorized Signature Date September 28, 2004			and the second s				
· · · · · · · · · · · · · · · · · · ·		Hamol 8h	mpe D				
	Typed or printed name _	Harriet M. Str	impel, D.F	Phil.			

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ming-qun Xu, Thomas C. Evans

Application No.: 09/786,009 Filed: April 17, 2001

Group No.: 1652 Examiner: Moore

For: Intein-Mediated Peptide Ligation

Mail Stop Issue Fee Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL OF PAYMENT OF ISSUE FEE (37 C.F.R. § 1.311)

- 1. Applicant hereby pays the issue fee for the attached Issue Fee Transmittal PTOL-85.
- 2. Applicant
 - A. Asserted small entity status in this application on February 28, 2001 by payment of the national filing fee as a small entity. (37 C.F.R. § 1.27(c)(3))

It is confirmed that small entity status for this application has been checked and it is still in effect and is being asserted.

CERTIFICATION UNDER 37 C.F.R. §§ 1.8(a) and 1.10*

(When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

Cadeposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. § 1.8(a)

37 C.F.R. § 1.10*

St with sufficient postage as first class mail.

G as "Express Mail Post Office to Addressee"

Mailing Label No.

(mandatory)

TRANSMISSION

G facsimile transmitted to the Patent and Trademark Office, (703)

Signature

Date: September 28, 2004

Leslie Goldberg

(type or print name of person certifying)

^{*} Only the date of filing ('1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under '1.8 continues to be taken into account in determining timeliness. See '1.703(f). Consider "Express Mail Post Office to Addressee" ('1.10) or facsimile transmission ('1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

3. Fee (37 C.F.R. § 1.18 (a)):

Application status is other than a small entity with a regular fee of \$665.00.

4. Payment of fee:

Attached is a check in the amount of \$695.00, covering the issue fee and ten copies of the patent.

A duplicate of this paper is attached.

Date: September 28, 2004

Reg. No.: 37,008 Tel. No.: 978-927-5054 Customer No.: 28986 Signature of Practitioner Harriet M. Strimpel

New England Biolabs, Inc.

32 Tozer Road Beverly, MA 01915